A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

What this study is about

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.

Who can join (things the study team will check)

✅ You may be able to join if…

• 18 years of age or older
• Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas
• Measurable disease
• ECOG Performance status 0-1
• Part 1: progression or relapse following standard treatments
• Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting
• Resolution of acute effects of prior anticancer therapy to baseline or Grade 1
• Consent to submit required pre-treatment tumor tissue as medically feasible

🚫 You may not be able to join if…

• Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan )
• Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion
• Pulmonary disease meeting protocol exclusion
• Other unacceptable abnormalities as defined by protocol

Where this trial is running

• City of Hope National Medical Center, Duarte, California, United States
• City of Hope at Irvine Lennar, Irvine, California, United States
• Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
• UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
• Santa Monica UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States
• UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
• Smilow Cancer Hospital - Yale New Haven Health, New Haven, Connecticut, United States
• Yale - New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States
• Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States
• Smilow Cancer Hospital - Trumbull, Trumbull, Connecticut, United States
• Brigham and Women's Hospital, Boston, Massachusetts, United States
• Dana-Farber Cancer Institute, Boston, Massachusetts, United States

+ 16 more sites.

Who to contact

Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07090499.